Cart
sales@molnova.com
AZ 13381758
CAS No. ——
AZ 13381758( AZ13381758 | CXCR2 SM | AZ-13381758 )
Catalog No. M17040 CAS No. ——
A potent, small molecule CXCR2 inhibitor with IC50 of 26 nM and 30 nM for mCXCR2 and hCXCR2, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAZ 13381758
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, small molecule CXCR2 inhibitor with IC50 of 26 nM and 30 nM for mCXCR2 and hCXCR2, respectively.
-
DescriptionA potent, small molecule CXCR2 inhibitor with IC50 of 26 nM and 30 nM for mCXCR2 and hCXCR2, respectively; inhibits the growth and metastatic potential pancreatic ductal adenocarcinoma, enhances sensitivity to anti-PD1 immunotherapy in vivo; chemical analog of AZD 5069.
-
In Vitro——
-
In Vivo——
-
SynonymsAZ13381758 | CXCR2 SM | AZ-13381758
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name5'-chloro-7'-methyl-1'-[[3-(trifluoromethyl)phenyl]methyl]spiro[imidazolidine-5,3'-indole]-2,2',4-trione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Steele CW, et al. Cancer Cell. 2016 Jun 13;29(6):832-845.
molnova catalog
related products
-
AZ 10397767
AZ10397767 is a potent, selective CXCR2 inhibitor that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.0.
-
MLN3126
MLN3126 (MLN 3126, MLN-3126) is a potent, selective, orally available CCR9 antagonist with IC50 of 6.3 nM (CCL25-induced calcium mobilization).
-
K-777
K-777 is a potent and selective CCR4 antagonist that inhibits both CCL17 binding and CCL17-induced chemotaxis in Hut78 cells with IC50 of 57 and 8.9 nM respectively.
